Skip to content
BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
Close

Search

Subscribe
BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

BioPharmChina BioPharmChina BioPharmChina

Covering China's BioPharma industry

  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
  • Home
  • Disease Areas
    • Oncology
    • Immunology
    • Autoimmune
    • I&I
    • Metabolic
    • Respiratory
    • Cardiovascular
    • Ophthalmology
    • Neurology
    • Rare Diseases
  • Clinical Trials
    • Phase 1
    • Phase 1/2
    • Phase 2
    • Phase 2/3
    • Phase 3
    • Phase 4
    • IIT
  • Financing
  • Manufacturing
  • Regulatory
    • FTD
    • BTD
    • IND
    • NDA/BLA
    • Approvals
  • Deals
    • M&A
    • Partnerships
  • Events
    • Conferences
    • Forums
    • Workshops
  • Companies
Close

Search

Subscribe
Home/Events/BioShanghai Week 2026
EventsForums

BioShanghai Week 2026

By Xiaoxin Du
August 26, 2026 2 Min Read
0

BioShanghai Week 2026 (or Shanghai International Biopharma Industry Week) will be held September 17–20, 2026 at Zhangjiang Science Hall, Shanghai.

Since its sixth edition, BioShanghai Week has become a iconic platform for biopharmaceutical innovation and industrial development. This year, for the first time, Report on the Work of the Government‌ designated the biopharmaceutical industry as an “emerging pillar industry,” explicitly calling for deeper integration of technological innovation and industrial innovation.

To better implement the mandate of “accelerating the innovative development of national high-tech zones” outlined in the 2025 Government Work Report, and to further leverage the leading and demonstrative role of the National Zhangjiang High-tech Industrial Development Zone, this year’s event is rebranded as “BioShanghai Week 2026,” with a vision rooted in Zhangjiang, radiating across China, and connecting globally.

Guided by the principles of “Professionalism, Internationalization, and Marketization”,  the conference will build a five-in-one core ecosystem spanning Industry + Clinical Research + Regulation + Capital + Cross-Border Trade. It will establish four major functional pillars — innovation achievement release, cutting-edge product showcase, industrial BD deal-making, and capital-financing empowerment. The conference is dedicated to establishing a new global benchmark for biotech business development, curating a world-class industry summit, and nurturing a vibrant industrial innovation ecosystem. By pooling premier resources, we are building a comprehensive global biomedical platform that integrates international exchange, strategic collaboration, and deal-making facilitation — establishing a new global benchmark for biotech business development, curating a world-class industry summit, and nurturing a vibrant industrial innovation ecosystem.

The overall framework of this year’s event features a “1+5+1+1” structure: one opening ceremony, five thematic tracks (Innovation & Integration, Clinical Translation, Capital Empowerment, Ecosystem Services, and Tripartite Synergy), one exhibition, and a series of Bio-Tours to local institutes and enterprises. This structure is designed to precisely meet the needs of scientists, entrepreneurs, investors, clinical PIs, and other stakeholders, fostering high-level exchange and pragmatic cooperation.

Date: Sept. 17–20, 2026

Location: Zhangjiang Science Hall, Shanghai, China

DETAILS

Tags:

ConferencesEvents
Other Articles
Previous

CPHI & PMEC Shenzhen 2026

Next

Akeso, Inc.

No Comment! Be the first one.

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

2026 H2 AbbVie China Partnering Day
2026 Global XDC Innovation Conference

Welcome to BioPharmChina, a dedicated news and information portal covering the rapidly evolving biotechnology and biopharmaceutical industry in China.

Get the latest news in China's BioPharma industry delivered straight to your inbox.

Latest Articles

  • Inno Medicine Secures Nearly $110M+ to Advance Targeted Nanomedicines for Atherosclerosis and Glioma
  • Unike Biopharma Raises Tens of Millions of RMB to Advance Long-Acting Protein and Peptide Drug Platform
  • 1cBio Licenses PARP1 Inhibitor OC-3 to Lee’s Pharm in $27 Million Asia Deal
  • Lumiere Therapeutics Raises Over RMB 100 Million to Advance Epigenetic Editing Therapies
  • Windward Bio’s WIN378 Delivers Positive Phase 2 Asthma Data as Twice-Yearly Anti-TSLP Antibody Moves Into Phase 3

Info

    About

    Privacy Policy

    Terms of Use

    Newsletter

    Contact

    Contact

    Email
    contact@biopharmchina.com

    Location
    San Francisco, CA, USA

    • X
    • Facebook
    Copyright 2026 — BioPharmChina. All rights reserved.